Webcast CME

 

 

 

 

Clinical Management of MDS/MPN:
A Mountain of Evidence for Treatment Selection in MDS/MPN



Print this Content


Release Date:   December 28, 2016
Expiration Date:  December 28, 2018

Estimated Time of Completion:  2 hours 30 minutes

Description

Clinical Management of MDS/MPN: A Mountain of Evidence for Treatment Selection in MDS/MPN webcast features an in-depth and up-to-date review of research related to the biology, prognosis, natural history, and therapeutic management of patients with myelodysplastic syndromes (MDS), myeloproliferative neoplasms (MPN), and MDS/MPN overlap.

Learning Objectives

  1. Summarize treatment options for patients classified with low-risk MDS, including both FDA-approved agents and those in development.
  2. Define recent advances in options for treating MPNs and identify their potential use in clinical practice.
  3. Debate the various issues regarding the clinical impact of molecular mutations on diagnosis, prognosis, and treatment choices for patients with MDS.
  4. Critically evaluate safety and efficacy data from trials using new and novel therapies for MDS.
  5. Discuss risks and benefits of alternative bone marrow transplant for elderly patients diagnosed with MDS/AML.

Target Audience

This educational activity is designed for an international audience including medical oncologists/hematologists, clinical and translational researchers, and other physicians and allied health care professionals treating patients with MDS and other bone marrow failure diseases. In addition, members of patient advocacy groups will benefit from this program.

Accreditation

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of The Cleveland Clinic Foundation Center for Continuing Education and Aplastic Anemia & MDS International Foundation. The Cleveland Clinic Foundation Center for Continuing Education is accredited by the ACCME to provide continuing medical education for physicians.

The Cleveland Clinic Foundation Center for Continuing Education designates this enduring material for a maximum of  2.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Participants claiming CME credit from this activity may submit the credit hours to the American Osteopathic Association for Category 2 credit.

Activity Director and Faculty

Activity Director

Sudipto Mukherjee, MD, PhD, MPH
Department of Hematology and Oncology
Taussig Cancer Institute
Cleveland Clinic
Cleveland, OH

Faculty

Lionel Ades, MD, PhD
Hôpital Saint-Louis
Paris, France

Aristoteles Giagounidis, MD
Professor and Department Head
Marien Hospital Düsseldorf
Düsseldorf, Germany

Leo Luznik, MD
Associate Professor
Department of Oncology Hematologic Malignancies
Johns Hopkins University School of Medicine
Baltimore, MD

Aziz Nazha, MD
Leukemia Program
Department of Hematology and Oncology
Taussig Cancer Institute
Cleveland Clinic
Cleveland, OH

Brady L. Stein, MD, MHS
Assistant Professor of Medicine
Robert H. Lurie Comprehensive Cancer Center
Division of Hematology/Oncology
Northwestern University Feinberg School of Medicine
Chicago, IL

CME Disclaimer

The information in this educational activity is provided for general medical education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition. The viewpoints expressed in this CME activity are those of the authors/faculty. They do not represent an endorsement by The Cleveland Clinic Foundation. In no event will The Cleveland Clinic Foundation be liable for any decision made or action taken in reliance upon the information provided through this CME activity.

Disclosures

In accordance with the Standards for Commercial Support issued by the Accreditation Council for Continuing Medical Education (ACCME), The Cleveland Clinic Foundation Center for Continuing Education requires resolution of all faculty conflicts of interest to ensure CME activities are free of commercial bias.

The following faculty have indicated that they may have a relationship which, in the context of their presentation, could be perceived as a potential conflict of interest:


Lionel Ades, MD, PhD
  Celgene Corporation Independent contractor (including contracted research)
  Millennium Membership on advisory committee or review panels
 
 
Aristoteles Giagounidis, MD
  Celgene Corporation Independent contractor (including contracted research)
  Teaching and Speaking
 
 
Brady L. Stein, MD, MHS
  Incyte Membership on advisory committee or review panels
  Participation in advisory committee

The following faculty have indicated they have no relationship which, in the context of their presentation, could be perceived as a potential conflict of interest:

Leo Luznik, MD
Sudipto Mukherjee, MD, PhD, MPH
Aziz Nazha, MD

Acknowledgements

The Cleveland Clinic Foundation Center for Continuing Education
and the Aplastic Anemia & MDS International Foundation
acknowledges educational grants for partial support of this activity from:


Celgene Corporation
Gilead Sciences
Incyte Corporation
MEI Pharma
Onconova Therapeutics

This CME activity was produced by the Cleveland Clinic Foundation Center for Continuing Education,
Cleveland Clinic’s Taussig Cancer Institute and Aplastic Anemia & MDS International Foundation.